@article{70714d7513854c429dca3156114803ca,
title = "Primary cutaneous lymphomas, version 2.2020. Featured updates to the NCCN guidelines",
abstract = "Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and S{\'e}zary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy is often necessary for the treatment of advanced-stage disease. Systemic therapy options have evolved in recent years with the approval of novel agents such as romidepsin, brentuximab vedotin, and mogamulizumab. These NCCN Guidelines Insights discuss the diagnosis and management of MF and SS (with a focus on systemic therapy).",
author = "Neha Mehta-Shah and Horwitz, {Steven M.} and Stephen Ansell and Ai, {Weiyun Z.} and Jeffrey Barnes and Barta, {Stefan K.} and Clemens, {Mark W.} and Ahmet Dogan and Kristopher Fisher and Goodman, {Aaron M.} and Gaurav Goyal and Joan Guitart and Ahmad Halwani and Haverkos, {Bradley M.} and Hoppe, {Richard T.} and Eric Jacobsen and Deepa Jagadeesh and Lunning, {Matthew A.} and Amitkumar Mehta and Olsen, {Elise A.} and Barbara Pro and Rajguru, {Saurabh A.} and Satish Shanbhag and Aaron Shaver and Andrei Shustov and Lubomir Sokol and Pallawi Torka and Carlos Torres-Cabala and Ryan Wilcox and William, {Basem M.} and Jasmine Zain and Dwyer, {Mary A.} and Hema Sundar and Kim, {Youn H.}",
note = "Publisher Copyright: {\textcopyright} National Comprehensive Cancer Network, Inc. 2020. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.",
year = "2020",
month = may,
doi = "10.6004/jnccn.2020.0022",
language = "English (US)",
volume = "18",
pages = "522--536",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "5",
}